Trial Profile
An Open-label, Phase II Study of KPS-0373 in Patients With SCD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2014
Price :
$35
*
At a glance
- Drugs Rovatirelin (Primary)
- Indications Spinocerebellar degeneration
- Focus Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 13 Nov 2014 New trial record